The first question is what was injected
If your filler brand is unknown, start by requesting treatment records and arranging a clinical assessment before elective dissolving. Hyaluronidase breaks down hyaluronic acid (HA); it does not remove calcium hydroxylapatite, poly-L-lactic acid, PMMA or silicone. The immediate decision is whether the unwanted material is HA, not whether you can remember a brand name. A clinician may still consider treatment when the brand is unknown but the material is sufficiently established.
You can book an assessment while looking for records. Imaging may help when the history or examination leaves uncertainty; it is not a compulsory step for every patient. Ask the clinician what supports the proposed diagnosis and what remains unknown. For the wider discussion of enzyme action and treatment risks, see dissolving filler with hyaluronidase.
What missing records changed in one clinical series
A Moorfields retrospective study reviewed 157 treated orbits in 90 referred patients from 2016–2020. Only HA fillers were included. The authors reported unknown brands in 35% and unknown original volumes in 55%. Mean hyaluronidase use was 444 units when volume was unknown versus 368 when known (P = 0.012). These are study observations, not personal dosing recommendations.
| Reported finding | What it supports | What it does not establish |
|---|---|---|
| 35% unknown brand; 55% unknown volume | Important details were often unavailable in this referral series. | Unknown brand did not mean non-HA: the study included HA only. |
| 444 versus 368 units with unknown versus known volume | Missing volume was associated with greater enzyme use. | Records alone caused the difference or would prevent harm. |
| 18% of treated-orbit outcomes classified as negative appearance changes | Hollowing, reduced elasticity or discoloration deserve discussion. | An 18% risk for every patient, facial area or treatment method. |
The outcome associations involved filler duration and volume; no association with enzyme dose or concentration was detected. The analysis was univariate, and the study cannot establish cause. Its periorbital referral setting also limits generalization. It did not compare a records-retrieval program with ordinary care or prove that recovering a chart improves outcomes.
For your consultation, the useful distinction is between information that is missing and information that is clinically necessary. A missing brand variant may leave uncertainty within the HA family. A completely unknown material is a different problem. A missing original volume does not tell you how much remains today. Ask the clinician to name the uncertainty rather than grouping all three situations under “unknown filler.”
Do not translate the study numbers into a request for more or less enzyme. They do not describe your deposit, symptoms or treatment goal. Instead, use them to ask how the plan would change if the original product name or volume became available. If the answer is that it would make no difference, ask why that information is unnecessary in your particular case.
Which records to ask for
Ask for existing treatment notes and product labels, not only a payment receipt. The following is a practical consultation checklist, rather than a promise that every clinic recorded every field. Keep a copy of the original documents; place your recollections in a separate timeline so a later reviewer can distinguish recorded facts from memory.
Product: the full trade name and variant, manufacturer, and recorded material. A brand family alone may not identify the formulation used.
Traceability: a lot or batch number, packaging sticker, and expiry date if recorded. A lot number can assist checking but does not, by itself, prove authenticity.
Treatment: dates, treated areas, amount placed in each area, and depth or plane if documented. Include later top-ups or dissolving treatments.
People and follow-up: injector name, practice contact details, consent, photographs used in care, and notes about symptoms or complications.
When a clinic sends a thin file, mark the missing fields explicitly. “Volume not recorded” is more useful than silently filling a blank from the size of a syringe you remember seeing. Likewise, a purchase invoice may help locate a visit but should not be treated as proof that a particular product was injected into a particular site. Bring both documents and let the treating clinician assess how they fit together.
For US providers covered by HIPAA, HHS explains the right to obtain medical and billing records. A provider cannot withhold your copy because of an unpaid treatment bill, and cannot charge for searching or retrieving it; reasonable copying and mailing charges may apply. These protections concern covered providers and plans, not every business using the term “med spa.” The HHS page also retains its Ciox Health court-order caveat.
For the fuller explanation of access, format, fees and documentation limits, use our guide to requesting aesthetic treatment records. For this dissolving decision, the immediate goal is a usable treatment history. Ask where to submit the request, what identity verification is needed, and when you should follow up. A request for information does not establish that the information exists.
If the original practice has closed
The AMA guidance on closed practices describes substantial access barriers. Look for a closure notice naming a custodian or successor, try the former practice location, and contact the relevant medical board or local health department for leads. Other clinicians may hold copies they previously received. An insurer may have claims information if the care was billed; many elective cosmetic visits will have no insurance claim.
Record retention depends on state requirements and other applicable rules, so there is no single nationwide look-back period for an old filler chart. Ask the custodian whether records from your treatment years remain available. Do not assume a closed practice destroyed everything, or that reaching a particular anniversary means your chart must have disappeared.
For treatment abroad, keep the original-language record and product packaging photographs if available. Ask the assessing clinician what translation is needed. Do not translate a vague description such as “collagen” into a precise material yourself. A domestic brand name or a familiar-looking box is not enough to reconstruct an undocumented injection. Travel-specific follow-up issues are covered in cross-border filler injections and documentation risk.
What ultrasound can and cannot tell you
Ultrasound can help locate deposits and suggest material types. A retrospective two-center pattern study included 60 patients; 48 had well-defined patterns and 12 had mixed patterns. Experienced observers described four broad appearances. This was a descriptive study, not a validated brand-identification test.
| Pattern described in the study | Associated materials or tissues |
|---|---|
| Heterogeneous | Healthy skin/subcutaneous tissue and fully integrated HA. |
| Fine-grain snowfall | Liquid injectable silicone. |
| Coarse-grain snowfall | Calcium hydroxylapatite and PMMA-based fillers. |
| Globular or cyst-like | Polyalkylamides, polyacrylamides and recently injected HA. |
These overlaps matter: a dark pocket is not automatically HA, and integrated HA can resemble normal tissue. The study lacked reproducibility testing between observers and used different machines. A pattern may support a material hypothesis, but it does not reliably establish a commercial brand, authenticity or an exact prior injected volume.
Ask for an explanation of the report in ordinary language: where is the suspected deposit, what material is suggested, how confident is that interpretation, and what alternatives remain? If several products were used at different visits, ask whether the assessment addresses each area. A conclusion about the cheek should not quietly become a conclusion about every previously treated facial site.
The practical endpoint is a documented clinical judgment, not a scan certificate that guarantees reversibility. If imaging and the history disagree, ask how the discrepancy will be investigated. It is reasonable to arrange an assessment without committing to an injection on the same day. An unresolved result is information worth recording, rather than something to conceal by choosing the most convenient product label.
A JMIR review of hyaluronidase applications describes ultrasound guidance as a way to improve targeting, while acknowledging limited randomized evidence. A 2025 review of proper hyaluronidase use also discusses guidance for difficult deposits. These reviews do not guarantee a lower dose, complete removal or a better result for every person. Ask whether imaging is needed and who will interpret it.
Which materials hyaluronidase can address
The table concerns hyaluronidase, not every possible approach to a complication. A filler may lose its cosmetic effect over time without being removable with this enzyme. Conversely, “permanent” does not mean that every symptom requires surgery. FDA warns that filler reduction or removal carries its own risks and may be difficult or impossible.
| Material | Examples | Hyaluronidase boundary |
|---|---|---|
| Hyaluronic acid | HA products in the Juvéderm, Restylane, Belotero and RHA families | Can break down the HA component; clinical response still varies. |
| Calcium hydroxylapatite | Radiesse | Does not remove the CaHA particles. |
| Poly-L-lactic acid | Sculptra | Does not reverse the PLLA material or the collagen response. |
| PMMA | Bellafill | Does not remove permanent PMMA microspheres. |
| Liquid silicone | Not FDA-approved as a cosmetic filler | Does not dissolve silicone. |
Ask the clinician to separate the material from any carrier, surrounding tissue response, and the symptom being assessed. “It contains some HA” would not establish that every component of a mixed treatment can be reversed. If the records show a non-HA product, the useful next conversation is about assessment and options for that material, rather than a routine HA-dissolving appointment. See biostimulators versus HA fillers and permanent PMMA filler for those broader decisions.
The FDA-approved filler page warns about unapproved Juvéderm Ultra 2, 3 and 4 products distributed in the US, and states that silicone is not approved for wrinkle filling or tissue augmentation. Missing paperwork does not prove an unapproved or counterfeit injection. Equally, recalling a familiar brand does not establish which formulation was used or its approved indication.
Old temporary filler may still matter
A published case report described MRI-confirmed residual HA 2.5 years after injection in a patient with facial cellulitis. One case cannot estimate how often this occurs or diagnose your swelling. It does show why an old treatment can remain relevant to a present assessment. The duration of a visible cosmetic effect is not proof that all material has disappeared.
Include old injections on your timeline even if you believed they had worn off. Mark approximate dates as approximate, and note which sites were treated. Your current concern may involve filler, a tissue response, natural changes or another condition; the clinician must assess it. New symptoms should not automatically be labelled migration, and a change after dissolving should not automatically be dismissed as ordinary aging. Our filler migration guide addresses that separate diagnostic question.
What still needs discussion after HA is established
The JMIR review describes cosmetic filler dissolution as off-label use. Establishing HA makes enzyme treatment relevant; it does not make the procedure risk-free. Discuss allergy history, previous dissolving reactions, expected swelling and bruising, and the plan for an unexpected response. Treatment choice, dose and follow-up belong to the assessing clinician.
In its patient explainer on dissolving filler, ASPS quotes surgeons describing how enzyme spread can make a precisely partial cosmetic correction difficult. This is a practical consent issue, not proof that every injection removes every deposit. Ask how the clinician will assess the result and what they can realistically control. Neither a promise of exact percentage removal nor a guarantee of return to an earlier photograph is established by these sources.
The cited evidence does not establish comparative dissolving outcomes for Fitzpatrick IV–VI. It cannot support claims of identical safety across skin types, a special enzyme dose, or a particular cannula technique for darker skin. Tell the clinician about previous pigmentation changes, scarring and healing problems, and ask how these will affect your individual assessment.
Before booking an elective dissolve
Bring the information you have to a consultation rather than waiting for a perfect file. The aim is to make a decision with the uncertainty visible. This practical sequence is for elective concerns; emergency symptoms follow the immediate-care advice above.
Describe the problem you want assessed: a visible contour, a lump, swelling, or dissatisfaction. Note when it began and whether it is changing. Do not choose a filler diagnosis in advance.
Create a treatment timeline and request the original notes. Include repeat visits, different clinics, earlier complications and previous dissolving attempts.
Separate confirmed facts, recollections and missing fields. Bring incomplete records too; do not convert a blank field into an assumed product or volume.
Ask what supports HA identification and whether imaging would resolve an uncertainty. If the material remains unclear, ask for the next assessment step and whether elective treatment should wait.
Discuss the proposed goal, risks, alternatives and follow-up. Ask what happens if the result is incomplete or the appearance is worse than expected.
Keep copies of the new assessment and any treatment record. Ask for the clinician’s conclusions about remaining uncertainty, so a subsequent consultation does not start from the same unexplained gap.
Before consenting, you should be able to explain the plan in your own words: what is being treated, why hyaluronidase is relevant, what could remain after it, and who will reassess you. Not knowing the brand is a reason to investigate, not a verdict that dissolving is impossible. The same uncertainty is also not evidence that an enzyme injection is the right first treatment.
Sources
Government guidance, clinical studies and reviews supporting this article are listed below. Study findings and professional commentary have different evidentiary roles; none provides an individualized treatment plan.
Dermal Fillers (Soft Tissue Fillers) — FDA: removal limitations and urgent vascular warning signs.
FDA-Approved Dermal Fillers — FDA: material categories and unapproved-product warnings.
The Posthyaluronidase Syndrome: Dosing Strategies for Hyaluronidase in the Dissolving of Facial Filler and Independent Predictors of Poor Outcomes — 2024: retrospective periorbital HA series, 157 orbits in 90 patients.
Ultrasound patterns of different dermal filler materials used in aesthetics — 2021: retrospective descriptive study of 60 patients; overlapping patterns and reproducibility limitations.
Hyaluronidase for Dermal Filler Complications: Review of Applications and Dosage Recommendations — 2024: literature review of off-label use, complications and ultrasound guidance.
Considerations for Proper Use of Hyaluronidase in the Management of Hyaluronic Acid Fillers — 2025: clinical review of filler properties and hyaluronidase use.
Your Medical Records (HIPAA for Individuals) — HHS: individual access, copying charges, unpaid bills and the Ciox Health caveat.
Obtaining Medical Records from Closed Practices — AMA, 2021: closed-practice records pathways and variable retention requirements.
Risks and rewards: What to know about dissolving filler — ASPS, 2025: patient explainer containing surgeon commentary on risks and partial correction.
Hyaluronic acid fillers may be longer-lasting than previously described: A case report of delayed filler-associated facial cellulitis — 2022: a single MRI-confirmed persistence and cellulitis case; not a frequency estimate.
